According to the Smart Finance app, UBS Group released a research report stating that it maintains a 'buy' rating for Weigao Group (01066), and has lowered the earnings forecast by 4%, 7%, and 9% for the years 2024 to 2026, reflecting lower forecast for medical instruments, interventional products, and blood management revenue; higher gross margin; higher research and development and management expense ratio; and lower sales expense ratio. The bank has reduced its target price from HKD 7.7 to HKD 7. The company's revenue in the first half of the year was CNY 6.64 billion, a year-on-year decrease of 3.8%, falling short of the bank's and market expectations. Net income was CNY 1.11 billion, a year-on-year decrease of 7.5%, also falling short of the bank's and market expectations.